Notice of Proposed Sale · 144
Roivant Sciences Ltd.
ROIVNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Roivant Sciences Ltd.
- Issuer CIK
- 0001635088
- SEC file number
- 001-40782
- Phone
- 441-295-5950
- Person for whose account securities are to be sold
- Venker Eric
- Relationships to issuer
- Officer
- Street
- 7TH FLOOR, 50 BROADWAY
- City
- LONDON
- State / country code
- X0
- Postal code
- SW1H 0DB
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 200,000 | 7,323,556.00 | 722,323,015 | 09/30/2026 | NASDAQ | Rockefeller Financial LLC |
Broker / market maker — proposed row 1, entry 1
- Name
- Rockefeller Financial LLC
- Street
- 45 Rockefeller Plaza
- Street (continued)
- Floor 5
- City
- New York
- State / country code
- NY
- Postal code
- 10111
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common Shares | 09/30/2026 | Options Exercise - Grant Date 04/20/2022 | Roivant Sciences Ltd. | 200,000 | N | 09/30/2026 | Wire |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| Eric Venker c/o Roivant Sciences Ltd. | Common Shares | 07/27/2026 | 200,000 | 6,989,924.05 |
| Eric Venker c/o Roivant Sciences Ltd. | Common Shares | 08/20/2026 | 13,909 | 512,407.56 |
| Eric Venker c/o Roivant Sciences Ltd. | Common Shares | 08/28/2026 | 200,000 | 7,147,087.91 |
Seller — prior-sale row 1, entry 1
- Name
- Eric Venker c/o Roivant Sciences Ltd.
- Street
- 7th Floor, 50 Broadway,
- City
- London
- State / country code
- X0
- Postal code
- SW1H0DB
Seller — prior-sale row 2, entry 1
- Name
- Eric Venker c/o Roivant Sciences Ltd.
- Street
- 7th Floor, 50 Broadway,
- City
- London
- State / country code
- X0
- Postal code
- SW1H0DB
Seller — prior-sale row 3, entry 1
- Name
- Eric Venker c/o Roivant Sciences Ltd.
- Street
- 7th Floor, 50 Broadway
- City
- London
- State / country code
- X0
- Postal code
- SW1H0DB
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Remarks
The shares reported on this Form 144 will be sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 03/28/2025.
Notice signature
- Notice date
- 09/30/2026
- Signed
- Carmen Zamores as a duly authorized representative of National Financial Services LLC, as attorney-in-fact for Venker Eric
- Plan adoption dates
- 03/28/2025
Company context
Roivant (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes LISRAYA™ (brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2 FDA-approved for the treatment of dermatomyositis in adult patients and also in late-stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. For more information, visit www.roivant.com.